e for the protease binding sites, enzymes process exogenous antigens by the AM (L 9-13, 15). Presumably, this would be a major pathway by which vaccine antigens could elicit T cell immunity-Recently, a second process has been recognized, by which nonendosomal proteases produce a different set of antigenic fragments for antigen presentation (5, (15) (16) (17) . Up to now, this pathway was thought to be accessible only to endogenous viral antigens produced by infected cells. However, if these two pathways are mutually exclusive, it would be difficult for exogenous vaccine antigens to elicit protective T cell immunity against infected cells expressing viral antigens endogenously.
In this paper we demonstrate that cloned human T cell lines, each specific for a single determinant on the surface antigen ofhepatitis B virus (HBsAg), can respond to exogenous as well as endogenous antigen . Exogenous antigen was used in the immunization and during the growth and selection of the T cell clones in itro. Nevertheless, each T cell line responded equally well to infected cells expressing exogenous antigen presented by the same AMs . In adigen processing requirements W each T cell genous and exogenous antigen. Different T cell endosomal or nonendosomal processing: for our T led 0 each processing pathway could not substi-on day 7 and cloned by limiting dilution at 1 or 0.3 cells per well. Cloning conditions included 2 x 104 irradiated PBL feeder cells in round-bottomed wells, containing 50% RPMI 1640 and 50°Jo EHAA media supplemented with 100 U/ml penicillin and 100 ttg/ml streptomycin, 2 mM glutamine, 5 x 10-5 M mercaptoethanol, 10% autologous serum, and 10% IL-2 (Cellular Products, Buffalo, NY). After 2-3 wk, proliferating cells were apparent in 67 of 480 wells. This cloning efficiency is typical of our results with human T cell clones . Of these, 24 were antigen specific, including 3 from the plates receiving 0.3 cells per well. The cloned lines were propagated by repeated cycles of stimulation in microwells followed by expansion in macrowells in the presence of 10% IL-2 . Two of the SR clones (SR45 and SR54) were used in the present studies, because their HLA restriction and antigen processing requirements were found to contrast with those of LLl.
Results Human T CellLines Speckfor HBsAg Vaccination with plasma-derived or recombinant HBsAg elicits a detectable T cell response in a small proportion of people tested (26) . As reported previously (25) , we tested 20 vaccinees and found 3 individuals whose T cells gave a significant in vitro proliferative response to exogenous HBsAg. For each responder, the population of antigen-specific T cells was expanded by antigen stimulation, and then cloned by the limiting dilution method. We obtained a T cell line LLI from one donor and T cell clones SR45 and SR54 from a second donor. Each of these clones was characterized for HLA restriction, epitope specificity, ability to recognize endogenous antigen, and antigen processing requirements for both endogenous and exogenous antigen.
HLA Restriction. T cell line LLI responds to HBsAg only when the HLA antigens of the APC match the HLA of the donor. We have determined which MHC antigen was recognized as a restriction element by LLI by studying PBL from family membersJL and JoL for the ability to present antigen to the line . As shown in Table  1 , Exp. 1, PBL from JL gave maximal antigen-specific stimulation, while PBL from JoL and the unrelated III gave none at all. Comparing the HLA types of each donor, we observed that HLA-A1, B35, and C4 were present on stimulatory and nonstimulatory presenting cells alike. HLA-All was present only on stimulatory PBL and could explain the observed pattern of stimulation. In other experiments, PBL from four of five unrelated HLA-All donors gave maximal stimulation by HBsAg (Table I , Exp. 2, shows three of these) . Thus, the LLI line recognizes HBsAg in association with HLA-All .
In contrast, the two clones SR45 and SR54 appeared to recognize HBsAg in association with HLA-DR7. The donor SR typed as HLADR6,7, and the clones respond to APCs bearing HLA-DR7 but not DR6 (as in Table IV and Fig. 2 below) . mAbs to MHC class I or class II antigens were then tested for the ability to block the antigen-specific response of each clone (Table II) . mAbs to HLA-A,B,C completely inhibited the LLI response to plasma-derived HBsAg, while anti-HLA-DR had little effect . Conversely, the monoclonal anti-HLA-DR inhibited the SR45 response to yeast-derived HBsAg, while anti-HLAABC inhibited poorly. Interestingly, anti-HLA-DR also completely inhibited the response of SR54 to endogenously expressed HBsAg (discussed further below), while anti-HLA-ABC was less effective. Thus, LLI responds to HBsAg in association with the MHC class I determinant HLA-All, while SR45 and SR54 are specific for MHC class 11.
Epitope Mapping! As shown in Table III A, yeast recombinant polypeptides de- rived from different regions of HBsAg were tested for the ability to stimulate each T cell line . LL1 was stimulated by long S (containing pre-Si + pre-S2 + S) and by pre-S1 alone, but not by S antigen. Conversely, SR54 was stimulated by long S and by S antigen alone, but not by pre-Si . SR45 was also stimulated by recombinant S antigen alone which is how it was derived. Thus, LLI recognizes an epitope in the pre-Si region, while SR54 and SR45 respond to epitopes in the S region of HBsAg.
Further precision in mapping the pre-SI epitope recognized by LLI required the
The same treated or untreated EBV-derived B cells (from donor LL) were used as the APC for all three T cell clones . For clone SR54, the EBV line was infected with vaccinia recombinant v73 as described in Materials and Methods . The APC were either pretreated overnight with monocloanl anti-HLA-DR (2 jig/ml), or cultured in the presence of anti-HLA-ABC (5 uglml use of synthetic peptides . Recent work with cloned T cell lines specific for a variety of antigens has shown that complete epitopes recognized by T cells may be contained on synthetic peptides corresponding to the antigenic determinant on the protein (reviewed in references 8 and 27 ). Thus, we tested an overlapping series of synthetic peptides corresponding to the pre-Si sequence for the ability to stimulate LL1. As shown in Fig. 1 , the response to recombinant yeast-derived pre-Si was equal to the response to the entire pre-Si + pre-S2 + S antigen. In addition, three of the synthetic pre-St peptides gave maximal stimulation, indicating that the entire antigenic determinant recognized by LL1 is contained on these peptides. The three peptides 1-28, 12-32, and 21-47 overlap at residues 21-28. We conclude that the epitope recognized by LLl is located in this region and has the sequence Pro-LeuGly-Phe-Phe-Pro-Asp-His (28).
Recognition of Endogenous HBsAg . An important question for vaccine-immune T cells is whether they can respond to infected cells that express viral antigens endogenously. To get endogenous expression of HBsAg in lymphocytes, we infected the cells with vaccinia recombinants that were constructed with either the S region only (v55) or with the entire long S region (v73), including pre-Si + pre-S2 + S. Previous studies have shown that cells infected with v55 produce S antigen and secrete 22-nm particles, while cells infected with v73 produce long S protein but the antigen remains a monomer and is not secreted (22). As shown in Table III to cells infected by vaccinia wild type . SR45 also responds to v55, but only when the infected stimulator cell matches at HLA-DR7 (Fig. 2 C) . The response to endogenous antigen was generally greater than or equal to the response to exogenous antigen for the doses tested . For all three clones, the response to v55-infected cells correlated with whether the clone responded to exogenous S antigen (Table III) . The results are compatible with each clone recognizing the same epitope for endogenous as well as exogenous antigen. The demonstration that the T cells are responding to endogenous antigen depends on the assumptions that (a) exogenous HBsAg does not contaminate the recombinant virus and (b) HBsAg is not secreted by an infected cell and taken up and processed as exogenous antigen by a second cell . This was supported by four lines of evidence : 
299
First, there was little or no detectable exogenous HBsAg associated with the pure virus, as measured by RIA (data not shown). Second, HBsAg production was under the control of viral genes : excessive UV irradiation of v55 (3-30-fold greater than the optimal dose) gave an exponential decrease in antigen production and an equal decrease in T cell stimulation (data not shown). Third, v73 is known to express endogenous pre-St + pre-S2 + S, but this long S antigen is not secreted into the culture medium, as shown by Western blots (22). Fourth, we tested whether the T cell response to v73-infected cells could be due to reuptake of secreted antigen (Table  IV) . We mixed infected 1101 cells of the mismatched HLA type (DR 6) with uninfected JL cells of the matched HLA type (DR7). The JL cells were competent presenters ofexogenous antigen as shown in the last line, and ofendogenous antigen as shown in the first line ofthe table. However, when mixed with infected 1101 cells they were unable to take up enough antigen to stimulate clone SR54. Thus, T cells recognize the endogenous antigen of infected cells directly, without resorting to a second APC.
Distinct Antigen Processing Pathways.
Previous studies have shown that T cells commonly recognize the same antigenic determinant whether contained on a native protein or a synthetic peptide (8, 27 ) . Synthetic peptides can also substitute for endogenously expressed viral antigens (5, 16, 17) . In both cases, the peptides are fully competent to stimulate a response, suggesting that partial proteolytic degradation is important for the presentation of native protein antigens from an endogenous or exogenous source. In addition, the steps of antigen processing have been divided into two distinct pathways based on sensitivity to inhibitors of endosomal proteases. The endosomal pathway has frequently been implicated in the processing ofexogenous native proteins for MHC class II-associated antigen presentation . It is readily inhibited by chloroquine or leupeptin (9-13) . The nonendosomal pathway is thought to process endogenously expressed viral proteins primarily, since CTL recognize infected target cells despite pretreatment with chloroquine, and also recognize uninfected targets when pulsed with synthetic peptides corresponding to viral antigens but not with the native protein antigens (5, 17 cessing pathway was postulated to work primarily on endogenous viral antigens, while the endosomal processing pathway was thought to handle exogenous antigens (5, 15, 17) . Since our T cell lines recognize both endogenous and exogenous HBsAg, we could test whether there is a strict segregation of processing pathways, or whether each processing pathway is accessible to both internal and external antigen . An example of such an experiment is shown in Table V The class I-restricted LL1 response to exogenous HBsAg is totally resistant to leupeptin inhibition, and so is the response to endogenous HBsAg produced by v73 infection . This suggests that the nonendosomal processing pathway is readily accessible to both exogenous and endogenous antigen . In contrast, the class II-restricted SR54 response to HBsAg is totally inhibited by leupeptin, regardless ofwhether the antigen comes from outside or inside the cell. Thus, the endosomal pathway is also accessible to both forms of antigen . The complete shutdown of the lysosomal pathway indicated by the inhibition ofthe Chloroquine inhibits the SR54 response but notthe LL 1 response to endogenous HBsAg. EBV-derived B cells from a single donor who was histocompatible to both LL and SR were infected with v73 for 1 h, followed by 1-h treatment with nothing or 0.1 mM diloroquine. They were washed and added to culture as stimulatorcells . V73-infected cells stimulated LLl despite chloroquine treatment, while the SR54 response to the same cells was 94°% inhibited . The LLl background with uninfected B cells was 3,212 cpm, and the SR54 background was 1,451 cpm. SR54 response has no effect on the response of LL1, other than to increase it by 65 % or more. Thus, the two processing pathways are independent, and the products of one pathway cannot substitute for the other in stimulation of T cells.
As shown in Table VI , we repeated this experiment with chloroquine as the inhibitor of endosomal proteases. However, we could only test the effect of chloroquine on endogenous antigen, since we were unable to pulse the APCs with exogenous antigen. Once again, full inhibition of the endosomal pathway was indicated by the 94% inhibition of SR54, but LLI continued to respond to the antigen maximally.
Thus, endogenous antigen can stimulate SR54 via a chloroquine sensitive pathway, or it can stimulate LL1 via a chloroquine insensitive pathway. The results in these two tables suggest that two distinct pathways exist for processing antigens that will eventually stimulate T cells like LLI or SR54 . Each T cell sees the product of one pathway only. But both pathways are accessible to endogenous and exogenous antigens .
Discussion
We have found that plasma-or yeast-derived hepatitis B vaccine can elicit human T cells immune to the preS or S regions of HBsAg. They recognize HBsAg in the context of MHC class I in some cases or class II antigens in other cases. Each cloned T cell line responds to endogenously expressed viral antigen as well as to exogenous antigen. Although each of the T cell lines recognizes processed antigen, more than one proteolytic pathway is available to process viral proteins into antigenic fragments that can be recognized by the T cell lines.
The antigenic determinant recognized by LLI mapped to the pre-Si region, based on the response to recombinant pre-Si and long S and the failure to respond to S alone. More precise epitope mapping was based on synthetic pre-Si peptides 1-28 and 21-47, which stimulate the line (as does 12-32), while other pre-Si peptides do not. The antigenic determinant consists of amino acids 21-28, which has the sequence Pro-Leu-Gly-Phe-Phe-Pro-Asp-His (28) . Presumably, this'peptide contains distinct functional sites for MHC association (with HLA-A11) and for binding by the antigen receptor of LLI (29) (30) (31) (32) ). This site is close to but distinct from the pre-Si site 12-21 identified by Milich et al . (33) as the pre-Si antigenic determinant recognized by mouse T cells in association with MHC class II antigens . They found that T cells specific for this site could provide T helper function to B cells specific for the S region (33) . The LLI T cell line is different in that it responds to peptide 21-28 in association with MHC class I antigens, and we do not as yet know whether it provides helper function .
The sequence of 21-28 fits well into the paradigm ofGly-hydrophobic-hydrophobicPro-charged amino acid proposed by Rothbard et al . (27, 34) . The closest reported analogue is peptide 111-120 of influenza hemagglutinin, which is presented in association with class II antigens in the mouse (35) . It is not clear whether peptides that associate with MHC class I antigens will follow the same or a different pattern from those that associate with class II antigens (7, 8) . However, in both cases, we presume that antigen processing is required because peptides can bind to MHC molecules but native proteins cannot (13, (30) (31) (32) . LLI responds well to synthetic peptides, and we presume that the independence of endosomal processing reflects use of a nonendosomal processing pathway, rather than the absence of processing.
Nonendosomal processing pathways are found in a large variety of cells (36 dinarily, they are important for the turnover of used or defective cellular proteins . But, in the infected cell, they may provide an important immunological signal of viral infection in the form of antigenic peptides on the cell surface in association with MHC antigens . Further progress may depend on finding selective inhibitors of the nonendosomal pathway, so that its unique physiological role can be determined . Our results on the processing of HBsAg for T cell stimulation are summarized in Fig. 3 . Exogenous antigen is endocytosed by the APC and partially degraded into antigenic fragments. Endogenously expressed antigen is processed in a similar manner. The processed peptides associate with MHC antigens on the surface of the APC . Receptor binding triggers the T cell response, including proliferation and IL-2 production . It does not matter to the T cell whether the antigen comes into the culture as a native protein or a peptide, since only peptides are able to associate with MHC and stimulate T cells. The model shows two possible processing pathways : one is endosomal and would be inhibited by leupeptin or chloroquine; the other is nonendosomal and insensitive to these inhibitors . As reported by others (5, 15, 37), individual T cells see the products of one pathway or the other, but not both. However, in contrast to those reports, we find that exogenous antigen is not limited to the endosomal pathway, but also can be processed via the nonendosomal pathway (Table  V) . Inhibition of the endosomal pathway has no effect on nonendosomal processing of exogenous antigen, suggesting that the two pathways are independent and operate in parallel with each other. Secondly, we find that endogenous antigen is not limited to the nonendosomal pathway, but can also be processed via the endosomal pathway (Tables V and VI) . Peptides produced from endogenous proteins show the same antigenicity (Table III and Fig. 2 ) and the same sensitivity to endosomal inhibitors as do peptides produced from exogenous proteins .
In light of the fact that all of our exogenous HBsAg-specific T cells crossreact with endogenous antigen, we have tried to understand why none of the influenza nucleoprotein and hemagglutinin-specific clones do so (5, 15). There are two major differences between the types of T cell clones studied . Ours were proliferative clones from noninfected donors who received a component vaccine. Theirs were cytolytic clones from mice that were acutely infected with live virus. The difference between proliferative and cytolytic T cells seems unlikely to explain a difference in antigen processing, since the TCR is substantially the same for both types of clones (38, 39) so the recognition of peptide-MHC complexes should be similar.
Alternatively, different T cell clones may be elicited by live virus than by vaccination with purified viral components . Fortunately, the vaccine-immune T cells crossreact with both endogenous and exogenous antigens, even though the infection-derived T cells apparently do not.
Each of our three clones (plus two others not shown) was able to recognize endogenously expressed HBsAg as well as exogenous antigen. This is in spite of immunization in vivo with noninfectious vaccine antigen and propagation of the T cell lines in vitro with exogenous antigen. Further, we have tested whether recognition of endogenous HBsAg could be explained as secretion by infected cells followed by reuptake and presentation of exogenous antigen by uninfected APCs . No evidence for this mechanism was detected in the mixing experiment (Table IV) . In addition, endogenous pre,S + S antigen expressed by v73 is not secreted but remains cell associated where it is recognized by the T cells. Recognition of endogenous antigen by T cells immune to exogenous HBsAg was a general finding with every one of our T cell lines and applied to both MHC class I-and class II-specific T cells. Thus, a noninfectious viral component vaccine can elicit active T cell immunity against infection with live virus.
Summary
We have studied the antigen specificity and processing requirements of three vaccineinduced cloned human T cell lines specific for HBsAg, the envelope protein of hepatitis B virus. Each T cell line recognized endogenously expressed antigen as well as exogenous antigen. Two clones required endosomal processing, both for exogenous and endogenous antigen; while the other T cell line depended on nonendosomal processing to generate antigenic peptides from both endogenous and exogenous antigen. Thus, the two processing pathways are accessible to exogenous and endogenous antigen. These results suggest that vaccine-induced T cells can participate actively in the immune response to live virus.
